01/12/2026
Exciting news from Emeryville! 🌟
We are thrilled to announce that the U.S. Food and Drug Administration
has granted Regenerative Medicine Advanced Therapy (RMAT) designation to our investigational therapy, ECT204, for the treatment of advanced liver cancer in adult patients.
This special designation is given to therapies that show potential to treat serious conditions and fill an unmet medical need. It allows us to work more closely with the FDA to speed up the development process.
At Eureka Therapeutics, we are committed to developing safer and more effective T-cell therapies. This milestone brings us one step closer to providing a potential new option for patients facing difficult-to-treat solid tumors.
Read the full release here: https://www.businesswire.com/news/home/20260112165656/en/U.S.-FDA-Grants-RMAT-Designation-to-ECT204-an-ARTEMIS-CAR-AbTCR-T-Cell-Therapy-for-Advanced-Hepatocellular-Carcinoma